Skip to main content
PMC home page
The EMBO Journal logoLink to The EMBO Journal
. 1996 Jun 3;15(11):2726–2737.

Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

C Toniatti 1, A Cabibbo 1, E Sporena 1, A L Salvati 1, M Cerretani 1, S Serafini 1, A Lahm 1, R Cortese 1, G Ciliberto 1
PMCID: PMC450208  PMID: 8654370

Abstract

Interleukin-6 (IL-6) triggers the formation of a high affinity receptor complex with the ligand binding subunit IL-6Ralpha and the signal transducing chain gp130. Since the intracytoplasmic region of the IL-6Ralpha does not contribute to signaling, soluble forms of the extracytoplasmic domain (sIL-6Ralpha), potentiate IL-6 bioactivity and induce a cytokine-responsive status in cells expressing gp130 only. This observation, together with the detection of high levels of circulating soluble human IL-6Ralpha (shIL-6Ralpha) in sera, suggests that the hIL-6-shIL-6Ralpha complex is an alternative form of the cytokine. Here we describe the generation of human IL-6 (hIL-6) variants with strongly enhanced shIL-6Ralpha binding activity and bioactivity. Homology modeling and site-directed mutagenesis of hIL-6 suggested that the binding interface for hIL-6Ralpha is constituted by the C-terminal portion of the D-helix and residues contained in the AB loop. Four libraries of hIL-6 mutants were generated by each time fully randomizing four different amino acids in the predicted AB loop. These libraries were displayed monovalently on filamentous phage surface and sorted separately for binding to immobilized shIL-6Ralpha. Mutants were selected which, when expressed as soluble proteins, showed a 10- to 40-fold improvement in shIL-6Ralpha binding; a further increase (up to 70-fold) was achieved by combining variants isolated from different libraries. Interestingly, high affinity hIL-6 variants show strongly enhanced bioactivity on cells expressing gp13O in the presence of shIL-6Ralpha at concentrations similar to those normally found in human sera.

Full text

PDF
2726

Images in this article

2727Image
on p.2727
2732Image
on p.2732

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. doi: 10.1016/s0065-2776(08)60532-5. [DOI] [PubMed] [Google Scholar]
  2. Arcone R., Pucci P., Zappacosta F., Fontaine V., Malorni A., Marino G., Ciliberto G. Single-step purification and structural characterization of human interleukin-6 produced in Escherichia coli from a T7 RNA polymerase expression vector. Eur J Biochem. 1991 Jun 15;198(3):541–547. doi: 10.1111/j.1432-1033.1991.tb16048.x. [DOI] [PubMed] [Google Scholar]
  3. Baumann G., Lowman H. B., Mercado M., Wells J. A. The stoichiometry of growth hormone-binding protein complexes in human plasma: comparison with cell surface receptors. J Clin Endocrinol Metab. 1994 May;78(5):1113–1118. doi: 10.1210/jcem.78.5.8175967. [DOI] [PubMed] [Google Scholar]
  4. Brakenhoff J. P., de Hon F. D., Fontaine V., ten Boekel E., Schooltink H., Rose-John S., Heinrich P. C., Content J., Aarden L. A. Development of a human interleukin-6 receptor antagonist. J Biol Chem. 1994 Jan 7;269(1):86–93. [PubMed] [Google Scholar]
  5. Bruce A. G., Hoggatt I. H., Rose T. M. Oncostatin M is a differentiation factor for myeloid leukemia cells. J Immunol. 1992 Aug 15;149(4):1271–1275. [PubMed] [Google Scholar]
  6. Cabibbo A., Sporeno E., Toniatti C., Altamura S., Savino R., Paonessa G., Ciliberto G. Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix. Gene. 1995 Dec 29;167(1-2):41–47. doi: 10.1016/0378-1119(95)00632-x. [DOI] [PubMed] [Google Scholar]
  7. Ciapponi L., Graziani R., Paonessa G., Lahm A., Ciliberto G., Savino R. Definition of a composite binding site for gp130 in human interleukin-6. J Biol Chem. 1995 Dec 29;270(52):31249–31254. doi: 10.1074/jbc.270.52.31249. [DOI] [PubMed] [Google Scholar]
  8. D'Hondt V., Humblet Y., Guillaume T., Baatout S., Chatelain C., Berlière M., Longueville J., Feyens A. M., de Greve J., Van Oosterom A. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood. 1995 May 1;85(9):2347–2353. [PubMed] [Google Scholar]
  9. De Benedetti F., Massa M., Pignatti P., Albani S., Novick D., Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994 May;93(5):2114–2119. doi: 10.1172/JCI117206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dittrich E., Rose-John S., Gerhartz C., Müllberg J., Stoyan T., Yasukawa K., Heinrich P. C., Graeve L. Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J Biol Chem. 1994 Jul 22;269(29):19014–19020. [PubMed] [Google Scholar]
  11. Edwards P. R., Gill A., Pollard-Knight D. V., Hoare M., Buckle P. E., Lowe P. A., Leatherbarrow R. J. Kinetics of protein-protein interactions at the surface of an optical biosensor. Anal Biochem. 1995 Oct 10;231(1):210–217. doi: 10.1006/abio.1995.1522. [DOI] [PubMed] [Google Scholar]
  12. Ehlers M., Grötzinger J., deHon F. D., Müllberg J., Brakenhoff J. P., Liu J., Wollmer A., Rose-John S. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol. 1994 Aug 15;153(4):1744–1753. [PubMed] [Google Scholar]
  13. Ehlers M., de Hon F. D., Bos H. K., Horsten U., Kurapkat G., van De Leur H. S., Grötzinger J., Wollmer A., Brakenhoff J. P., Rose-John S. Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells. J Biol Chem. 1995 Apr 7;270(14):8158–8163. doi: 10.1074/jbc.270.14.8158. [DOI] [PubMed] [Google Scholar]
  14. Evan G. I., Lewis G. K., Ramsay G., Bishop J. M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol. 1985 Dec;5(12):3610–3616. doi: 10.1128/mcb.5.12.3610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Felici F., Castagnoli L., Musacchio A., Jappelli R., Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol. 1991 Nov 20;222(2):301–310. doi: 10.1016/0022-2836(91)90213-p. [DOI] [PubMed] [Google Scholar]
  16. Fiorillo M. T., Toniatti C., Van Snick J., Ciliberto G. Expression of the murine interleukin 6 receptor in hepatoma cells: the intracytoplasmic domain is not required for interleukin 6 signal transduction. Eur J Immunol. 1992 Mar;22(3):799–804. doi: 10.1002/eji.1830220325. [DOI] [PubMed] [Google Scholar]
  17. Gaillard J. P., Bataille R., Brailly H., Zuber C., Yasukawa K., Attal M., Maruo N., Taga T., Kishimoto T., Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol. 1993 Apr;23(4):820–824. doi: 10.1002/eji.1830230408. [DOI] [PubMed] [Google Scholar]
  18. Gearing D. P., Comeau M. R., Friend D. J., Gimpel S. D., Thut C. J., McGourty J., Brasher K. K., King J. A., Gillis S., Mosley B. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 1992 Mar 13;255(5050):1434–1437. doi: 10.1126/science.1542794. [DOI] [PubMed] [Google Scholar]
  19. Givon T., Slavin S., Haran-Ghera N., Michalevicz R., Revel M. Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood. 1992 May 1;79(9):2392–2398. [PubMed] [Google Scholar]
  20. Gordon M. S., Nemunaitis J., Hoffman R., Paquette R. L., Rosenfeld C., Manfreda S., Isaacs R., Nimer S. D. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 1995 Jun 1;85(11):3066–3076. [PubMed] [Google Scholar]
  21. Hammacher A., Ward L. D., Weinstock J., Treutlein H., Yasukawa K., Simpson R. J. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Protein Sci. 1994 Dec;3(12):2280–2293. doi: 10.1002/pro.5560031213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990 Dec 21;63(6):1149–1157. doi: 10.1016/0092-8674(90)90411-7. [DOI] [PubMed] [Google Scholar]
  23. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 1992 Apr 1;148(7):2175–2180. [PubMed] [Google Scholar]
  24. Horiuchi S., Koyanagi Y., Zhou Y., Miyamoto H., Tanaka Y., Waki M., Matsumoto A., Yamamoto M., Yamamoto N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994 Aug;24(8):1945–1948. doi: 10.1002/eji.1830240837. [DOI] [PubMed] [Google Scholar]
  25. Horn D., Fitzpatrick W. C., Gompper P. T., Ochs V., Bolton-Hansen M., Zarling J., Malik N., Todaro G. J., Linsley P. S. Regulation of cell growth by recombinant oncostatin M. Growth Factors. 1990;2(2-3):157–165. doi: 10.3109/08977199009071502. [DOI] [PubMed] [Google Scholar]
  26. Ishibashi T., Kimura H., Uchida T., Kariyone S., Friese P., Burstein S. A. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5953–5957. doi: 10.1073/pnas.86.15.5953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995 Aug 15;86(4):1243–1254. [PubMed] [Google Scholar]
  28. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992 Oct 23;258(5082):593–597. doi: 10.1126/science.1411569. [DOI] [PubMed] [Google Scholar]
  29. Lahm A., Savino R., Salvati A. L., Cabibbo A., Ciapponi L., Demartis A., Toniatti C., Paonessa G., Altamura S., Ciliberto G. The molecular design of human IL-6 receptor antagonists. Ann N Y Acad Sci. 1995 Jul 21;762:136–151. doi: 10.1111/j.1749-6632.1995.tb32322.x. [DOI] [PubMed] [Google Scholar]
  30. Lasfar A., Wietzerbin J., Billard C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur J Immunol. 1994 Jan;24(1):124–130. doi: 10.1002/eji.1830240119. [DOI] [PubMed] [Google Scholar]
  31. Leebeek F. W., Kariya K., Schwabe M., Fowlkes D. M. Identification of a receptor binding site in the carboxyl terminus of human interleukin-6. J Biol Chem. 1992 Jul 25;267(21):14832–14838. [PubMed] [Google Scholar]
  32. Lowman H. B., Wells J. A. Affinity maturation of human growth hormone by monovalent phage display. J Mol Biol. 1993 Dec 5;234(3):564–578. doi: 10.1006/jmbi.1993.1612. [DOI] [PubMed] [Google Scholar]
  33. Mackiewicz A., Górny A., Laciak M., Malicki J., Murawa P., Nowak J., Wiznerowicz M., Hawley R. G., Heinrich P. C., Rose-John S. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther. 1995 Jun;6(6):805–811. doi: 10.1089/hum.1995.6.6-805. [DOI] [PubMed] [Google Scholar]
  34. Mackiewicz A., Schooltink H., Heinrich P. C., Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992 Sep 15;149(6):2021–2027. [PubMed] [Google Scholar]
  35. Mackiewicz A., Wiznerowicz M., Roeb E., Karczewska A., Nowak J., Heinrich P. C., Rose-John S. Soluble interleukin 6 receptor is biologically active in vivo. Cytokine. 1995 Feb;7(2):142–149. doi: 10.1006/cyto.1995.1019. [DOI] [PubMed] [Google Scholar]
  36. Marks J. D., Griffiths A. D., Malmqvist M., Clackson T. P., Bye J. M., Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y) 1992 Jul;10(7):779–783. doi: 10.1038/nbt0792-779. [DOI] [PubMed] [Google Scholar]
  37. May L. T., Patel K., García D., Ndubuisi M. I., Ferrone S., Mittelman A., Mackiewicz A., Sehgal P. B. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood. 1994 Sep 15;84(6):1887–1895. [PubMed] [Google Scholar]
  38. Mott H. R., Campbell I. D. Four-helix bundle growth factors and their receptors: protein-protein interactions. Curr Opin Struct Biol. 1995 Feb;5(1):114–121. doi: 10.1016/0959-440x(95)80016-t. [DOI] [PubMed] [Google Scholar]
  39. Mulé J. J., McIntosh J. K., Jablons D. M., Rosenberg S. A. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990 Mar 1;171(3):629–636. doi: 10.1084/jem.171.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., Taga T., Kishimoto T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993 Jun 18;260(5115):1808–1810. doi: 10.1126/science.8511589. [DOI] [PubMed] [Google Scholar]
  41. Müllberg J., Schooltink H., Stoyan T., Günther M., Graeve L., Buse G., Mackiewicz A., Heinrich P. C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993 Feb;23(2):473–480. doi: 10.1002/eji.1830230226. [DOI] [PubMed] [Google Scholar]
  42. Northrup S. H., Erickson H. P. Kinetics of protein-protein association explained by Brownian dynamics computer simulation. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3338–3342. doi: 10.1073/pnas.89.8.3338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. O'Shannessy D. J., Brigham-Burke M., Soneson K. K., Hensley P., Brooks I. Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. Anal Biochem. 1993 Aug 1;212(2):457–468. doi: 10.1006/abio.1993.1355. [DOI] [PubMed] [Google Scholar]
  44. Paonessa G., Graziani R., De Serio A., Savino R., Ciapponi L., Lahm A., Salvati A. L., Toniatti C., Ciliberto G. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J. 1995 May 1;14(9):1942–1951. doi: 10.1002/j.1460-2075.1995.tb07186.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Porgador A., Tzehoval E., Katz A., Vadai E., Revel M., Feldman M., Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992 Jul 1;52(13):3679–3686. [PubMed] [Google Scholar]
  46. Rodbard D., Frazier G. R. Statistical analysis of radioligand assay data. Methods Enzymol. 1975;37:3–22. doi: 10.1016/s0076-6879(75)37003-1. [DOI] [PubMed] [Google Scholar]
  47. Ryffel B., Car B. D., Woerly G., Weber M., DiPadova F., Kammüller M., Klug S., Neubert R., Neubert D. Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate--the marmoset. Blood. 1994 Apr 15;83(8):2093–2102. [PubMed] [Google Scholar]
  48. Saggio I., Gloaguen I., Poiana G., Laufer R. CNTF variants with increased biological potency and receptor selectivity define a functional site of receptor interaction. EMBO J. 1995 Jul 3;14(13):3045–3054. doi: 10.1002/j.1460-2075.1995.tb07307.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Salvati A. L., Lahm A., Paonessa G., Ciliberto G., Toniatti C. Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface. J Biol Chem. 1995 May 19;270(20):12242–12249. doi: 10.1074/jbc.270.20.12242. [DOI] [PubMed] [Google Scholar]
  50. Sato N., Miyajima A. Multimeric cytokine receptors: common versus specific functions. Curr Opin Cell Biol. 1994 Apr;6(2):174–179. doi: 10.1016/0955-0674(94)90133-3. [DOI] [PubMed] [Google Scholar]
  51. Savino R., Ciapponi L., Lahm A., Demartis A., Cabibbo A., Toniatti C., Delmastro P., Altamura S., Ciliberto G. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 1994 Dec 15;13(24):5863–5870. doi: 10.1002/j.1460-2075.1994.tb06931.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Savino R., Lahm A., Giorgio M., Cabibbo A., Tramontano A., Ciliberto G. Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4067–4071. doi: 10.1073/pnas.90.9.4067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Savino R., Lahm A., Salvati A. L., Ciapponi L., Sporeno E., Altamura S., Paonessa G., Toniatti C., Ciliberto G. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J. 1994 Mar 15;13(6):1357–1367. doi: 10.1002/j.1460-2075.1994.tb06389.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Schwabe M., Zhao J., Kung H. F. Differential expression and ligand-induced modulation of the human interleukin-6 receptor on interleukin-6-responsive cells. J Biol Chem. 1994 Mar 11;269(10):7201–7209. [PubMed] [Google Scholar]
  55. Schöbitz B., Pezeshki G., Pohl T., Hemmann U., Heinrich P. C., Holsboer F., Reul J. M. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J. 1995 May;9(8):659–664. doi: 10.1096/fasebj.9.8.7768358. [DOI] [PubMed] [Google Scholar]
  56. Sporeno E., Paonessa G., Salvati A. L., Graziani R., Delmastro P., Ciliberto G., Toniatti C. Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors. J Biol Chem. 1994 Apr 15;269(15):10991–10995. [PubMed] [Google Scholar]
  57. Stoyan T., Michaelis U., Schooltink H., Van Dam M., Rudolph R., Heinrich P. C., Rose-John S. Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification. Eur J Biochem. 1993 Aug 15;216(1):239–245. doi: 10.1111/j.1432-1033.1993.tb18138.x. [DOI] [PubMed] [Google Scholar]
  58. Studier F. W., Moffatt B. A. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol. 1986 May 5;189(1):113–130. doi: 10.1016/0022-2836(86)90385-2. [DOI] [PubMed] [Google Scholar]
  59. Sui X., Tsuji K., Tanaka R., Tajima S., Muraoka K., Ebihara Y., Ikebuchi K., Yasukawa K., Taga T., Kishimoto T. gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2859–2863. doi: 10.1073/pnas.92.7.2859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989 Aug 11;58(3):573–581. doi: 10.1016/0092-8674(89)90438-8. [DOI] [PubMed] [Google Scholar]
  61. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11924–11928. doi: 10.1073/pnas.90.24.11924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Tepper R. I., Mulé J. J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994 Feb;5(2):153–164. doi: 10.1089/hum.1994.5.2-153. [DOI] [PubMed] [Google Scholar]
  63. Ward L. D., Howlett G. J., Discolo G., Yasukawa K., Hammacher A., Moritz R. L., Simpson R. J. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem. 1994 Sep 16;269(37):23286–23289. [PubMed] [Google Scholar]
  64. Ward L. D., Howlett G. J., Hammacher A., Weinstock J., Yasukawa K., Simpson R. J., Winzor D. J. Use of a biosensor with surface plasmon resonance detection for the determination of binding constants: measurement of interleukin-6 binding to the soluble interleukin-6 receptor. Biochemistry. 1995 Mar 7;34(9):2901–2907. doi: 10.1021/bi00009a021. [DOI] [PubMed] [Google Scholar]
  65. Wells J. A. Additivity of mutational effects in proteins. Biochemistry. 1990 Sep 18;29(37):8509–8517. doi: 10.1021/bi00489a001. [DOI] [PubMed] [Google Scholar]
  66. Yasukawa K., Saito T., Fukunaga T., Sekimori Y., Koishihara Y., Fukui H., Ohsugi Y., Matsuda T., Yawata H., Hirano T. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem. 1990 Oct;108(4):673–676. doi: 10.1093/oxfordjournals.jbchem.a123261. [DOI] [PubMed] [Google Scholar]
  67. Zhang X. G., Gaillard J. P., Robillard N., Lu Z. Y., Gu Z. J., Jourdan M., Boiron J. M., Bataille R., Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994 Jun 15;83(12):3654–3663. [PubMed] [Google Scholar]
  68. de Hon F. D., Klaasse Bos H. K., Ebeling S. B., Grötzinger J., Kurapkat G., Rose-John S., Aarden L. A., Brakenhoff J. P. Leucine-58 in the putative 5th helical region of human interleukin (IL)-6 is important for activation of the IL-6 signal transducer, gp130. FEBS Lett. 1995 Aug 7;369(2-3):187–191. doi: 10.1016/0014-5793(95)00741-q. [DOI] [PubMed] [Google Scholar]
  69. de Vos A. M., Ultsch M., Kossiakoff A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992 Jan 17;255(5042):306–312. doi: 10.1126/science.1549776. [DOI] [PubMed] [Google Scholar]
  70. van Gameren M. M., Willemse P. H., Mulder N. H., Limburg P. C., Groen H. J., Vellenga E., de Vries E. G. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 1994 Sep 1;84(5):1434–1441. [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES